Ou S, Le X, Nagasaka M, Reungwetwattana T, Ahn M, Lim D
Lung Cancer (Auckl). 2024; 15:87-114.
PMID: 38938224
PMC: 11208875.
DOI: 10.2147/LCTT.S463429.
Kopranovic A, Meyer-Almes F
Int J Mol Sci. 2024; 25(11).
PMID: 38891780
PMC: 11171933.
DOI: 10.3390/ijms25115593.
Joynson B, Cumming G, Ball L
Angew Chem Int Ed Engl. 2023; 62(31):e202305081.
PMID: 37294032
PMC: 11497286.
DOI: 10.1002/anie.202305081.
Sandor A, Ionut I, Marc G, Oniga I, Eniu D, Oniga O
Pharmaceuticals (Basel). 2023; 16(4).
PMID: 37111291
PMC: 10141396.
DOI: 10.3390/ph16040534.
Feng Y, Huang L, Zhu H, Tang L, Hu X, Shi Y
Thorac Cancer. 2022; 13(18):2641-2649.
PMID: 36082809
PMC: 9475224.
DOI: 10.1111/1759-7714.14603.
Allele-specific activation, enzyme kinetics, and inhibitor sensitivities of EGFR exon 19 deletion mutations in lung cancer.
Brown B, Zhang Y, Kim S, Finneran P, Yan Y, Du Z
Proc Natl Acad Sci U S A. 2022; 119(30):e2206588119.
PMID: 35867821
PMC: 9335329.
DOI: 10.1073/pnas.2206588119.
Targeting tumor endothelial hyperglycolysis enhances immunotherapy through remodeling tumor microenvironment.
Shan Y, Ni Q, Zhang Q, Zhang M, Wei B, Cheng L
Acta Pharm Sin B. 2022; 12(4):1825-1839.
PMID: 35847509
PMC: 9279856.
DOI: 10.1016/j.apsb.2022.02.014.
Distribution and favorable prognostic implication of genomic EGFR alterations in IDH-wildtype glioblastoma.
Higa N, Akahane T, Hamada T, Yonezawa H, Uchida H, Makino R
Cancer Med. 2022; 12(1):49-60.
PMID: 35695190
PMC: 9844636.
DOI: 10.1002/cam4.4939.
Radiotherapy-drug combinations in the treatment of glioblastoma: a brief review.
McAleavey P, Walls G, Chalmers A
CNS Oncol. 2022; 11(2):CNS86.
PMID: 35603818
PMC: 9134931.
DOI: 10.2217/cns-2021-0015.
Covalent Proximity Scanning of a Distal Cysteine to Target PI3Kα.
Borsari C, Keles E, McPhail J, Schaefer A, Sriramaratnam R, Goch W
J Am Chem Soc. 2022; 144(14):6326-6342.
PMID: 35353516
PMC: 9011356.
DOI: 10.1021/jacs.1c13568.
Treatment of Choroidal Metastasis from Epidermal Growth Factor Mutant Non-Small Cell Lung Cancer with First-line Osimertinib Therapy.
Vu A, Mehta U, Israelsen P, Ou S, Browne A
J Ophthalmic Vis Res. 2022; 17(1):130-134.
PMID: 35194503
PMC: 8850857.
DOI: 10.18502/jovr.v17i1.10178.
Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance.
Cui Q, Hu Y, Cui Q, Wu D, Mao Y, Ma D
Front Pharmacol. 2022; 12:746707.
PMID: 35046801
PMC: 8762231.
DOI: 10.3389/fphar.2021.746707.
Molecular mechanisms of chemo- and radiotherapy resistance and the potential implications for cancer treatment.
Liu Y, Zheng C, Huang Y, He M, Xu W, Li B
MedComm (2020). 2021; 2(3):315-340.
PMID: 34766149
PMC: 8554658.
DOI: 10.1002/mco2.55.
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives.
Zhong L, Li Y, Xiong L, Wang W, Wu M, Yuan T
Signal Transduct Target Ther. 2021; 6(1):201.
PMID: 34054126
PMC: 8165101.
DOI: 10.1038/s41392-021-00572-w.
What's in a Name? Drug Nomenclature and Medicinal Chemistry Trends using INN Publications.
Serafini M, Cargnin S, Massarotti A, Tron G, Pirali T, Genazzani A
J Med Chem. 2021; 64(8):4410-4429.
PMID: 33847110
PMC: 8154580.
DOI: 10.1021/acs.jmedchem.1c00181.
Translational pharmacokinetic-pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose.
Xiong W, Friese-Hamim M, Johne A, Stroh C, Klevesath M, Falchook G
CPT Pharmacometrics Syst Pharmacol. 2021; 10(5):428-440.
PMID: 33818908
PMC: 8129711.
DOI: 10.1002/psp4.12602.
Identification of Intrinsic Drug Resistance and Its Biomarkers in High-Throughput Pharmacogenomic and CRISPR Screens.
Ayestaran I, Galhoz A, Spiegel E, Sidders B, Dry J, Dondelinger F
Patterns (N Y). 2020; 1(5):100065.
PMID: 33205120
PMC: 7660407.
DOI: 10.1016/j.patter.2020.100065.
Importin 13 promotes NSCLC progression by mediating RFPL3 nuclear translocation and hTERT expression upregulation.
Zohud B, Guo P, Zohud B, Li F, Hao J, Shan X
Cell Death Dis. 2020; 11(10):879.
PMID: 33082305
PMC: 7575581.
DOI: 10.1038/s41419-020-03101-9.
Real-World EGFR T790M Testing in Advanced Non-Small-Cell Lung Cancer: A Prospective Observational Study in Japan.
Seto T, Nogami N, Yamamoto N, Atagi S, Tashiro N, Yoshimura Y
Oncol Ther. 2020; 6(2):203-215.
PMID: 32700028
PMC: 7359964.
DOI: 10.1007/s40487-018-0064-8.
Clinical activity of the tyrosine kinase inhibitor osimertinib in -mutant glioblastoma.
Makhlin I, Salinas R, Zhang D, Jacob F, Ming G, Song H
CNS Oncol. 2019; 8(3):CNS43.
PMID: 31769726
PMC: 6880297.
DOI: 10.2217/cns-2019-0014.
